🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCan we talk about how SLOW the FDA is — my results so far Page 4

Can we talk about how SLOW the FDA is — my results so far

NurseAsh_DET Tue, Nov 18, 2025 at 7:47 PM 43 replies 1,294 viewsPage 4 of 9
Dr.NephBHM_UK
Member
456
2,123
Jun 2024
Birmingham, UK
Nov 29, 2025 at 3:09 PM#16

From the other side of the consultation, briefly. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.

5 3Dr.CardioMD, EndoResFellow, PharmacoVig_BOS and 2 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Dec 1, 2025 at 5:24 AM#17
BiostatsBrad said:
Keep the original post as written when you update it, and add the correction underneath.

Agreed on the substance. I would put less weight on the timescale, because two months of anything is not enough to distinguish a trend from a wobble.

That is the short version; the long version is somebody else's post.

6 4SleepDoc_PDX, RegAffairsDC, BiostatsBrad and 3 others
Reply Quote Save Share Report
claudia_zurich
Member
389
1,678
Jul 2024
Zurich, CH
Dec 2, 2025 at 7:40 PM#18
BiostatsBrad said:
Keep the original post as written when you update it, and add the correction underneath.

Genuinely useful, thank you. I had the facts and not the framework. Taking it to my next appointment.

7 5Dr.LipidDallas, alex_tucson, kevin_tulsa and 4 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
Dec 4, 2025 at 9:54 AM#19

From the other side of the consultation, briefly. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

8 6julia.endo, JessicaM_2024, TomFromTexas and 5 others
Reply Quote Save Share Report
SallyK_inj
Member
567
2,345
Jul 2024
Iowa
Dec 6, 2025 at 12:08 AM#20

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. No action needed from anybody.

30 3Dr.PathRoch, mona_PHX, andrew_nyc and 27 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register